American National Bank Has $810,000 Stock Position in Merck & Co., Inc. (NYSE:MRK)

American National Bank lifted its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 8.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,884 shares of the company’s stock after acquiring an additional 664 shares during the quarter. American National Bank’s holdings in Merck & Co., Inc. were worth $810,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Advisor Resource Council acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $378,000. True North Advisors LLC purchased a new position in Merck & Co., Inc. in the fourth quarter valued at about $1,532,000. Alberta Investment Management Corp lifted its stake in shares of Merck & Co., Inc. by 4.4% during the 4th quarter. Alberta Investment Management Corp now owns 406,967 shares of the company’s stock valued at $31,190,000 after buying an additional 17,267 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Merck & Co., Inc. by 3.8% during the 4th quarter. Invesco Ltd. now owns 20,201,129 shares of the company’s stock valued at $1,548,216,000 after purchasing an additional 739,839 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in Merck & Co., Inc. by 9.8% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 177,463 shares of the company’s stock valued at $13,600,000 after buying an additional 15,800 shares during the period. Institutional investors own 73.33% of the company’s stock.

Merck & Co., Inc. Stock Performance

MRK opened at $87.72 on Monday. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $222.22 billion, a PE ratio of 13.43, a P/E/G ratio of 1.18 and a beta of 0.33. The firm has a 50 day moving average of $89.45 and a two-hundred day moving average of $87.64. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.20. The company had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The firm’s quarterly revenue was up 28.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.31 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 annualized dividend and a dividend yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is currently 42.27%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Atlantic Securities lifted their price target on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. UBS Group boosted their price objective on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the company a “neutral” rating in a research report on Monday, July 18th. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and boosted their target price for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and increased their price target for the company from $95.00 to $100.00 in a research report on Wednesday, September 14th. Finally, Cowen increased their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.28.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.